Welcome to our dedicated page for AMPIO PHARMS news (Ticker: AMPE), a resource for investors and traders seeking the latest updates and insights on AMPIO PHARMS stock.
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a pre-revenue stage biotechnology company based in Greenwood Village, Colorado. The company is focused on developing innovative treatments for osteoarthritis through its OA-201 program. This program aims to develop a unique and proprietary small molecule formulation designed to alleviate pain and protect cartilage in patients suffering from osteoarthritis of the knee (OAK) and potentially other joints.
Recently, Ampio faced significant developments, including a 20-to-1 reverse stock split approved by its Board of Directors to address its stock price and meet NYSE American's listing requirements. The reverse stock split took effect in September 2023. Despite these efforts, Ampio decided to voluntarily delist its common stock from NYSE American and deregister its shares to reduce regulatory costs and conserve cash for future operations.
In the clinical field, Ampio has partnered with Ascendia Pharmaceuticals, Inc. to support the development of OA-201. Ascendia will provide comprehensive services ranging from formulation to cGMP manufacturing. Despite promising initial results, recent non-clinical studies failed to demonstrate significant pain reduction benefits, leading to the termination of the OA-201 program in February 2024.
Ampio has also been involved in legal proceedings, including securities fraud class actions and derivative actions, all of which reached settlements in early 2024. The company anticipates that the settlements will be covered by its D&O insurance policy.
The company recently announced that it will delist its common stock and terminate its reporting obligations under the Securities and Exchange Act of 1934, effective April 2024. This decision aims to preserve cash and facilitate an orderly wind down of operations.
For more information, visit the company's website or contact Ampio Pharmaceuticals directly via email at mmartino@ampiopharma.com.
Ampio Pharmaceuticals (AMPE) reminds stockholders to vote on proposals ahead of its 2021 Annual Meeting set for August 14, 2021, at 9:00 a.m. (MT). Stockholders as of June 21, 2021, received proxy materials for the virtual event, which allows questions but restricts voting to recorded stockholders. Registration is required using a control number found in the proxy materials. The company appreciates stockholder support and will post a meeting replay online. Ampio focuses on immunology-based therapies for inflammatory conditions with ongoing development of its lead drug, Ampion.
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on immunology-based therapies, will host one-on-one investor meetings at two upcoming conferences. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13-15, 2021, and the Cantor Fitzgerald Virtual Global Healthcare Conference will take place from September 27-30, 2021. Ampio's lead drug, Ampion™, which aims to treat prevalent inflammatory conditions, has a patent portfolio extending through 2037 and could secure 12-year FDA market exclusivity upon approval.
Ampio Pharmaceuticals (AMPE) reported its Q2 2021 financial results, highlighting significant advancements in its clinical trials. The company completed a Phase I trial for inhaled Ampion in COVID-19 patients, showing a 78% reduction in all-cause mortality. Following this success, Phase II trials have commenced, with enrollment expected to increase, including expansion to India. Cash and equivalents reached $20.5 million, up 18% from the previous year. The company's net loss was $3.6 million, a 30% increase from Q2 2020, while it anticipates enough liquidity to fund operations through Q4 2022.
Ampio Pharmaceuticals, a biopharmaceutical company focused on immunology therapies, announced its virtual presentation at the American College of Toxicology 42nd Annual Meeting from November 14 to 17, 2021. The poster titled 'Efficient Applied Toxicology during COVID-19' discusses results from the AP-014 Phase I trial of its inhaled drug, Ampion. The study revealed a 78% reduction in all-cause mortality in COVID-19 patients with respiratory distress compared to Standard of Care. Ampio is moving forward with a Phase II trial due to these promising results.
Ampio Pharmaceuticals (AMPE) announced a virtual presentation for their abstract titled "Significant Inhibition of the TLR7/CXCL10 Signaling Axis by LMWF5A" at the upcoming 14th International Congress on Systemic Lupus Erythematosus (LUPUS 2021) on October 6-9, 2021. The presentation will explore Ampion™, currently in clinical trials for COVID-19 treatment, and its effects on cytokine release. Early data from the AP-014 Phase I trial indicates that inhaled Ampion reduced all-cause mortality in COVID-19 respiratory distress by 78% compared to standard care.
Ampio Pharmaceuticals (AMPE) announced its poster presentation titled "Inflammation and COVID Induced ARDS: Inhaled Ampion™ as a Therapeutic Option" at the 63rd annual Thomas L. Petty Aspen Lung Conference from September 20 to 23, 2021, in Aspen, Colorado. The poster showcases results from the AP-014 Phase I clinical trial, indicating that inhaled Ampion significantly reduced all-cause mortality in COVID-19 respiratory distress by 78%. Patients receiving Ampion had shorter hospital and ICU stays compared to the control group, and fewer needed Remdesivir treatment.
Ampio Pharmaceuticals (AMPE) will host a conference call on August 4, 2021, at 4:30 pm EDT to discuss its financial results for Q2 2021 and provide a corporate update. The call will be accessible domestically at 888-506-0062 and internationally at 973-528-0011, using conference ID 469825. Investors can also listen via the webcast available on Ampio's website. The company is focused on immunology-based therapies for inflammatory conditions, with its lead product, Ampion, backed by an extensive patent portfolio.
Ampio Pharmaceuticals (NYSE American: AMPE) announced the initiation of patient randomization and dosing in its multi-center AP-019 Phase II clinical trial for inhaled Ampion™ to treat respiratory distress from COVID-19. Following strong Phase I results showing a 78% reduction in all-cause mortality, the Phase II trial aims to confirm these outcomes. The company has also received FDA approval to expand the study to India amid rising COVID-19 cases. Ampion is positioned as an immunomodulatory agent to improve clinical outcomes for patients with severe respiratory issues.
Ampio Pharmaceuticals (AMPE) announced its anticipated inclusion in the Russell 2000 and Russell 3000 Indexes, effective June 28, 2021. This milestone is expected to enhance the company's visibility within the investment community. The Russell indexes are fundamental benchmarks for investment strategies, with approximately $10.6 trillion in assets tied to them. Ampio focuses on immunology-based therapies, particularly its lead drug Ampion™, which holds a patent until 2035 and may qualify for 12-year FDA market exclusivity as a novel biologic.
Ampio Pharmaceuticals (AMPE) announced integrated data from four earlier clinical trials of Ampion for severe osteoarthritis of the knee (OAK). This analysis involved 585 patients and demonstrated significant pain reduction compared to saline at multiple intervals. The data highlights Ampion's efficacy, with reductions in pain of up to 38.1% at ten weeks. The FDA has agreed that one pivotal trial supports a future Biologics License Application (BLA). Despite COVID-19 delaying other trials, Ampio remains optimistic about upcoming results and aims to be the first novel OAK therapy in over 20 years.
FAQ
What is the current stock price of AMPIO PHARMS (AMPE)?
What is the market cap of AMPIO PHARMS (AMPE)?
What is Ampio Pharmaceuticals' focus area?
What is the recent change in Ampio's stock structure?
Who is Ampio's partner in developing OA-201?
What happened to Ampio's OA-201 program?
What legal issues has Ampio faced recently?
Why is Ampio delisting its stock from the NYSE American?
When will Ampio's delisting become effective?
Will Ampio continue to report to the SEC?
Is Ampio still developing treatments for osteoarthritis?
How can I get more information about Ampio Pharmaceuticals?
